
Opinion|Videos|November 27, 2024
Overview of FCS
Key Takeaways
- Familial Chylomicronemia Syndrome is genetically confirmed, while Persistent Chylomicronemia is often clinically diagnosed due to secondary factors.
- FCS prevalence in the US is about 1-2 per million, with significant disease burden including recurrent pancreatitis.
Panelists discuss how familial chylomicronemia syndrome (FCS) and persistent chylomicronemia are diagnosed either genetically or clinically, outlining the prevalence and disease burden of FCS in the US, as well as its signs, symptoms, and diagnostic criteria, and how to differentiate FCS from other forms of hyperlipidemia.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please provide an overview of Familial Chylomicronemia Syndrome, or FCS, and Persistent Chylomicronemia. (please note which is genetically confirmed vs clinically diagnosed and; expand on them two).
- What is the prevalence and disease burden of FCS in the United StatesUS?
- What are the signs/symptoms and diagnostic criteria of FCS?
- How do you differentiate FCS from other forms of hyperlipidemia?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Semaglutide 7.2 mg Shows Greater BMI, Cardiometabolic Gains in T2D
5






















































